<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136552</url>
  </required_header>
  <id_info>
    <org_study_id>FL2000</org_study_id>
    <secondary_id>PHRC</secondary_id>
    <nct_id>NCT00136552</nct_id>
  </id_info>
  <brief_title>Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden</brief_title>
  <official_title>FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess in a prospective multicentric study (Phase III) the&#xD;
      introduction of a monoclonal antibody directed against B-cells associated with a standard&#xD;
      therapy including chemotherapy and alpha-interferon in first line treatment of patients with&#xD;
      a large tumor burden follicular lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Follicular lymphoma patients with a large tumor burden will be randomized for 18 months of&#xD;
      treatment with either:&#xD;
&#xD;
        -  Arm A: CHVP + alpha2a-interferon. Patients will receive 12 courses of CHVP&#xD;
           (cyclophosphamide 600 mg/m², adriamycin 25 mg/m², etoposide 100 mg/m² on day 1 and&#xD;
           prednisolone 40 mg/m² for 5 days), one course every month for 6 months then one course&#xD;
           every other month for 12 additional months associated with alpha2a-interferon 4.5&#xD;
           millions units sub-cutaneously three times a week for 18 months.&#xD;
&#xD;
        -  Arm B: CHVP + alpha2a-interferon + rituximab. Patients will receive 6 monthly courses of&#xD;
           CHVP (cyclophosphamide 600 mg/m², adriamycin 25 mg/m², etoposide 100 mg/m² on day 1 and&#xD;
           prednisolone 40 mg/m² for 5 days) associated with 6 infusions of rituximab (375 mg/m2)&#xD;
           associated with alpha2a-interferon 4.5 millions units sub-cutaneously three times a week&#xD;
           for 18 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date>December 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment>360</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed follicular lymphoma with a biopsy performed in the last 3&#xD;
             months&#xD;
&#xD;
          -  Patients previously untreated.&#xD;
&#xD;
          -  Patients with at least one of the following symptoms requiring initiation of&#xD;
             treatment:&#xD;
&#xD;
               -  Bulky disease at study entry according to the Groupe d'Etudes Lymphomes&#xD;
                  Folliculare (GELF) criteria: nodal or extranodal mass &gt; 7cm in its greater&#xD;
                  diameter&#xD;
&#xD;
               -  B symptoms&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) &gt; 1&#xD;
&#xD;
               -  Elevated serum lactate dehydrogenase (LDH) or beta2-microglobulin&#xD;
&#xD;
               -  Involvement of at least 3 nodal sites (each with a diameter greater than 3 cm)&#xD;
&#xD;
               -  Symptomatic splenic enlargement&#xD;
&#xD;
               -  Compressive syndrome&#xD;
&#xD;
               -  Pleural/peritoneal effusion&#xD;
&#xD;
          -  Age must be &gt; 18 years and less than 76 years&#xD;
&#xD;
          -  Having previously signed a written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Transformation to high-grade lymphoma (secondary to &quot;low-grade&quot; follicular lymphoma).&#xD;
&#xD;
          -  Patients without a large tumor burden.&#xD;
&#xD;
          -  Patients with prior or concomitant malignancies except non-melanoma skin cancer or&#xD;
             adequately treated in situ cervical cancer.&#xD;
&#xD;
          -  Poor renal function: Serum creatinine &gt; 150 μmol/L,&#xD;
&#xD;
          -  Known HIV infection or active hepatitis B virus (HBV) or hepatitis C virus (HCV)&#xD;
             infection.&#xD;
&#xD;
          -  Patients with contra-indication to interferon, adriamycin, or rituximab.&#xD;
&#xD;
          -  Serious underlying medical conditions, which could impair the ability of the patient&#xD;
             to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus,&#xD;
             gastric ulcers, active autoimmune disease). Judgment is up to the investigator.&#xD;
&#xD;
          -  Known sensitivity or allergy to murine products&#xD;
&#xD;
          -  Adult patient under tutelage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles A Salles, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe d'Etude des Lymphomes de l'adulte</name>
      <address>
        <city>Mont-Godinne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie - Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, Peuchmaur M, Bosly A, Parlier Y, Brice P, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med. 1993 Nov 25;329(22):1608-14.</citation>
    <PMID>8232429</PMID>
  </reference>
  <reference>
    <citation>McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33.</citation>
    <PMID>9704735</PMID>
  </reference>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>July 2, 2007</last_update_submitted>
  <last_update_submitted_qc>July 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2007</last_update_posted>
  <keyword>lymphoma</keyword>
  <keyword>follicular</keyword>
  <keyword>B-cell</keyword>
  <keyword>rituximab</keyword>
  <keyword>interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

